MA
VRDN icon

Montag & Associates’s Viridian Therapeutics VRDN Stock Holding History

Montag & Associates’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12
Closed -$259 – 1161
2025
Q3 		$259 Buy
+12
New +$216 ﹤0.01% 1112

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Montag & Associates's VRDN Position: Q4 2025 in Review

Montag & Associates sold out of Viridian Therapeutics (VRDN) in Q4 2025, closing a stake of 12 shares — an estimated $259 sold.

Montag & Associates first reported a position in VRDN in Q3 2025 and held it in 1 quarter. The position peaked at $259 in Q3 2025. 229 funds tracked by Wall St. Rank hold VRDN as of Q4 2025.

  • Montag & Associates reported no remaining Viridian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Montag & Associates sold 12 Viridian Therapeutics shares in Q4 2025, an estimated $259.
  • Montag & Associates first reported a position in Viridian Therapeutics in Q3 2025 and held it in 1 quarter.
  • Montag & Associates's Viridian Therapeutics position peaked at $259 in Q3 2025.
  • 229 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2025.

Based on Montag & Associates's 13F filing for Q4 2025, filed 2 Feb 2026.